Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
187 Leser
Artikel bewerten:
(1)

The Menninger Clinic Offering Nation's First Rapid Targeted Transcranial Magnetic Stimulation to Treat Depression

Menninger is the only hospital in the U.S. to offer groundbreaking treatment

HOUSTON, TX / ACCESSWIRE / November 13, 2024 / Rapid Targeted Transcranial Magnetic Stimulation (TMS), a groundbreaking new treatment for depression, will now be available at The Menninger Clinic's Center for Brain Stimulation. The Houston-based mental health hospital is currently the only hospital in the U.S. to offer this treatment, which has shown to speed remission rates from depression.

The Rapid Targeted TMS utilizes functional magnetic resonance imaging (fMRI) to identify the specific part of an individual's brain that would benefit most from the treatment. Individuals undergoing Rapid Targeted TMS receive 10 minutes of treatment per hour for 10 hours over five consecutive days, targeted at their own unique brain area. Traditional TMS does not provide such precise targeting nor the same dosage and the treatment time is longer - once a day, five days a week for six weeks. Rapid Targeted TMS can be completed in either an outpatient or inpatient setting at Menninger.

"Rapid Targeted TMS using functional magnetic resonance imaging is the first groundbreaking clinical use of personalized TMS in psychiatry," said Dr. Neil Puri, medical director The Menninger Clinic's Center for Brain Stimulation. "The ability to specifically target the areas of the brain implicated in depression, combined with the intensity of this treatment, can lead to significant remission rates for depression."

Since Menninger began offering this type of FDA-approved TMS delivery to individuals, 10 out of 12 individuals at Menninger have achieved remission, and nine out of 11 had a resolution of suicidal thinking. While providing a more rapid result than conventional TMS, Menninger has seen the remission effects lasting more than a month without a booster treatment.

The Center for Brain Stimulation offers other life-changing and potentially lifesaving options for patients who don't respond to medications and therapy. The Center provides neuromodulation therapies, including electroconvulsive therapy (ECT), traditional transcranial magnetic stimulation (TMS) and ketamine infusion.

"Patients with treatment-resistant depression often try a variety of medications and therapies without any success, which can exacerbate their depression symptoms and prolong their effects on daily living," said Armando E. Colombo, president and CEO, The Menninger Clinic. "Menninger continues to seek new forms of treatment that can have a lasting impact on people, and the addition of Rapid Targeted TMS to our treatment options will be life-changing for many."

For more information about The Menninger Clinic and available services, please visit www.menningerclinic.org or call 713-275-5400.

###

About The Menninger Clinic -

The Menninger Clinic has 99 years of experience diagnosing and treating people with mental illness and addictions. Highly trained teams of mental health experts provide a supportive, healing environment coupled with evidence-based treatments across a wide range of services for adults and adolescents that reduce troubling symptoms and strengthen skills for making changes that last. Menninger is a teaching hospital of Baylor College of Medicine's Menninger Department of Psychiatry and Behavioral Sciences and is a member institution in the Texas Medical Center. All psychiatrists and psychologists are on the faculty of Baylor College of Medicine. For more information, visit www.MenningerClinic.org.

Media Contact

Hannah Savage
Carbonara Group
hannah@carbonaragroup.com
713-819-1320 (c)

SOURCE: The Menninger Clinic



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.